Here, withdrawal means taking treatment away
A withdrawal study asks what happens when an intervention is removed after a period of treatment. The term describes the research design; it does not, by itself, describe a withdrawal syndrome or addiction. Read the study timeline before treating a headline as advice about your prescription.
Two frequently cited studies help explain why the plan beyond an initial prescription matters. They studied adults with overweight or obesity who did not have diabetes, using defined trial medicines. Neither studied CoreAge Rx patients.
STEP 1 extension: a year after semaglutide stopped
The STEP 1 extension analyzed 327 participants from a larger trial. At week 68, study treatment and the lifestyle intervention ended. Over the following year, the former semaglutide group regained about two-thirds of its previous weight loss on average.
Two-thirds refers to weight previously lost, not two-thirds of someone’s body weight. This was an exploratory follow-up of a subset of participants, and lifestyle support stopped too. It cannot isolate the effect of stopping medication from every other change or tell you exactly what would happen in your circumstances.
SURMOUNT-4: continuing tirzepatide versus switching to placebo
In SURMOUNT-4, 670 participants who completed 36 weeks of tirzepatide were randomly assigned to continue it or switch to placebo for another 52 weeks. From that assignment point, average weight increased 14.0% in the placebo group and decreased a further 5.5% in the continuing-treatment group.
Those percentages use weight at week 36 as the reference point. They are not percentages of the weight previously lost. The randomized participants had already completed the initial treatment period, which matters when applying the findings to someone just considering medication.
What these findings leave unanswered
The studies used different medicines, timelines and designs. Comparing their headline numbers cannot tell you which medicine is easier to stop. An average also leaves room for different individual outcomes. Neither result supplies a personal taper, a restart schedule or a guarantee that another treatment will prevent regain.
NIDDK’s medication overview describes treatment duration in terms of benefit and side effects. Use the research to ask how ongoing care will be assessed, rather than to decide in advance that everyone needs the same length of treatment. Our evidence-reading guide explains the difference between a study finding and a personal forecast.
Put the next decision on the care plan
A reason to reconsider treatment might be cost, tolerability, a changing health condition or a change in your priorities. Bring that reason into the clinical conversation early. A calendar reminder to order medication is different from an appointment to evaluate whether the plan still fits.
- Which benefits and side effects will we review before deciding whether to continue?
- If treatment changes or stops, what follow-up and other support will remain available?
- What changes in symptoms or health should prompt an earlier clinical review?
- How will I obtain a written plan and records if I move to another service?
Separate CoreAge Rx supply periods from treatment duration
For a practical service example, CoreAge Rx’s refill instructions describe check-ins tied to medication deliveries. That ordering schedule does not establish how long treatment is medically appropriate. Use its doctor-messaging route to raise clinical questions, and confirm the payment and renewal terms of your selected offer separately.
Our long-term planning guide connects those questions with goals, costs and continuity. The CoreAge Rx service review provides additional service context once you understand the treatment questions.
CoreAge Rx describes compounded offerings. FDA explains that compounded drugs are not approved and have not undergone its premarket review for safety, effectiveness and quality. The withdrawal trials above do not establish outcomes or equivalence for a compounded product.
Common questions
Does everyone regain all the weight after stopping?
No universal outcome follows from a group average. Withdrawal research found average regain under particular study conditions; it cannot predict an individual’s amount or timeline.
Does this mean GLP-1 treatment must last forever?
The studies support discussing ongoing care, but they cannot prescribe a duration for you. Review benefits, adverse effects, alternatives and your circumstances with the prescribing clinician.
Is finishing a prepaid supply the same as finishing treatment?
No. A supply or payment period is an ordering arrangement. Make the clinical decision about continuing, changing or stopping separately, and confirm what follow-up will be available.
Sources and fact-checking
Sources checked 2026-09-09. CoreAge Rx pages support descriptions of its service; medical and regulatory sources support the educational context. Offers and availability can change.